Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tinengotinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TT-00420 is under development for the treatment of solid tumors including triple-negative breast cancer, cholangiocarcinoma, HER2-negative breast cancer, bladder cancer, small cell lung cancer, prostate cancer, thyroid cancer, sarcoma, gastric cancer, gallbladder cancer, hepatocellular carcinoma, metastatic or advanced renal clear cell carcinoma (RCC), metastatic or advanced urothelial carcinoma (UC) and metastatic castration-resistant prostate cancer (mCRPC). The therapeutic candidate is administered through oral route. It acts by targeting aurora kinase A and aurora kinase B.
TransThera Sciences (Nanjing) overview
TransThera Sciences (Nanjing) (TransThera Sciences) is a biotechnology company, dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via the internal research platform and open innovation. The company develops and commercializes small molecule therapeutic agents for cancer, cardiovascular and inflammatory diseases. It focuses on the discovery and development of highly differentiated small-molecule new drugs and serving the medical needs of patients worldwide. Its oncology product portfolio includes TT-00420, TT-00434, TT-01488, TT-009373, and TT-ROMI. Its non-oncology products are TT-00920, TT-01688, TT-01025 and TT-RIAN. TransThera Sciences is headquartered in Nanjing, Jiangsu, China.
For a complete picture of Tinengotinib’s drug-specific PTSR and LoA scores, buy the report here.